FLORHAM PARK, NJ, January 13, 2021 / PRNewswire / – Celularity Inc., a clinical stage cell therapy company focused on the development of allogeneic cell therapies derived from the innovative placenta, today announced that its Lifebank division has launched its 100th unit cord blood stem cells for use in an autologous cord blood transplant to treat an eight-year-old patient diagnosed with autism spectrum disorder.
Researchers around the world are investigating cord stem cells as a potential treatment option for autism spectrum disorder. Autism is a complex developmental brain disorder that causes varying degrees of communication difficulties, social and behavioral challenges and repetitive behaviors. It is estimated that 1 child in 68 falls somewhere along the autism spectrum.
A clinical trial conducted by Duke University (NCT02176317) found that cord blood infusion was safe in children aged 2 to 7 years with autism. Another trial (NCT02847182) is investigating whether such an infusion can benefit these children by improving communication skills.
The stem cells entrusted to Lifebank have been used clinically, including to treat childhood leukemias, sickle cell anemia and inherited immune deficiencies. The researchers continue to investigate the potential benefit of cord blood stem cells for the treatment of other diseases and disorders.
Robert J. Hariri, M.D., Ph.D., Founder, President and CEO of Celularity, said: “This is a remarkable milestone for Celularity. I am proud that Lifebank has served families that trust us to store their newborns’ umbilical cord blood for more than two decades. “He added:” We hope to continue to gain that trust and support research around the expanded use of umbilical cord blood as a treatment for serious illnesses and disorders. “
Lifebank, a private stem cell banking service founded by Dr. Hariri in 1998, is a division of Celularity. Lifebank offers umbilical cord blood, placental blood and placental tissue banks for pregnant families in its state-of-the-art biorepository, where biomaterials are kept safely and continuously monitored to be available, if necessary, to treat the child or a close family member. To learn more, visit lifebankusa.com
Celularity, based in Florham Park, N.J., is a clinical stage biotechnology company that leads the next evolution in cellular medicine by providing allogeneic cellular therapies derived from the placenta in unparalleled scale, quality and economy. Celularity’s innovative approach to cell therapy harnesses the unique therapeutic potential blocked in the postpartum placenta. Through nature’s immunotherapy mechanism – the placenta – Celularity is leading the next evolution of cell medicine with placenta-derived T cells, NK cells and pluripotent stem cells to address unmet and unmet clinical needs in cancer, diseases infectious and degenerative. To learn more, visit celularity.com.
Celularity media contact:
View the original content to download multimedia: http://www.prnewswire.com/news-releases/celularity-announces-release-of-100th-cord-blood-stem-cell-unit-by-its-lifebank-division-301207490.html